Which flu strains are included in this season's UK vaccine and how do they match circulating strains?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
The 2025–26 UK flu vaccine was formulated to include influenza A H1N1, influenza A H3N2 and an influenza B component; UKHSA and other coverage say the H1N1 component is well matched, while a drifted H3N2 variant called “subclade K” has emerged that is only a partial match to the vaccine and is driving current UK cases (vaccine composition: [1]; matching: [2]; subclade K mismatch and spread: [8], [6], [7]2).
1. What’s in this season’s UK shot — the short list
Public reporting of the Northern Hemisphere 2025–26 vaccine composition describes a trivalent/quadrivalent mix that targets an A(H1N1) strain, an A(H3N2) strain and at least one B lineage; multiple outlets summarise that “the 2025-2026 flu vaccine contains H1N1, H3N2 and influenza B” [1]. The UK Health Security Agency (UKHSA) has separately reported surveillance and lab analysis about circulating clades alongside vaccine performance [2].
2. The match scorecard: where vaccine and virus line up
UKHSA’s laboratory analysis explicitly states the predominant circulating strain at one point was A H1N1 clade 5a.2a and that the H1N1 component of the vaccine is well matched to those viruses [2]. Reporting from outlets citing UKHSA and vaccine-effectiveness data shows the shot is performing reasonably well in children (70–75% effectiveness for preventing hospital attendance) and more modestly in adults (around 30–40% effectiveness), indicating the vaccine still provides protection even where drift is present [3] [4] [5].
3. The mismatch problem: what is subclade K and why it matters
Scientists identified a drifted H3N2 variant called subclade K after manufacturers had already been told which strains to include in the vaccine; this subclade accumulated several new mutations and has spread rapidly in the UK, Canada and Japan, creating concern that the H3N2 component in the vaccine is not an optimal match [6] [7] [8]. Analyses cited in press reporting concluded the H3N2 now circulating has “accumulated enough new mutations…to the point of being ‘mismatched’” from the H3N2 strain used in this year’s shots [4].
4. Real‑world impact: cases, hospitalisations and vaccine benefit
The mismatch has coincided with an unusually early and steep rise in UK flu cases and hospitalisations — Reuters and the BBC report hospitalisations up sharply (55% week‑on‑week increases in some reports) and warnings of a severe season — yet UKHSA and other sources emphasise vaccines still reduce severe outcomes and hospital pressure [9] [10] [3]. Public-health statements quoted in multiple outlets urge vaccination because, even when antigenic drift reduces protection against infection, vaccines continue to reduce severe illness and admissions [4] [5].
5. Competing interpretations in the press
Some outlets frame subclade K as a near‑takeover that could sharply worsen seasons worldwide; Medscape, Stat and other reporters note projections that subclade K may dominate 2025–26 and warn of reduced vaccine protection [7] [6]. UK authorities and UKHSA reporting provide the counterpoint that, so far, vaccine effectiveness against severe outcomes in children is high and the H1N1 component is well matched, suggesting the shot retains important protective value [2] [3] [5].
6. What sources don’t say and remaining uncertainties
Available sources do not mention exact antigenic‑cartography or laboratory neutralisation titres for every circulating H3N2 isolate in the UK, nor do they provide a single, definitive vaccine‑effectiveness percentage across all age groups for the whole season to date; instead they report age‑stratified effectiveness estimates and laboratory matching statements (not found in current reporting: detailed neutralisation tables) [2] [4] [5]. Scientists also note sequencing is needed to confirm how much of H3N2 circulation elsewhere represents subclade K specifically [8].
7. Practical takeaways for the public
Health authorities and experts quoted in the coverage agree on action: get vaccinated now if eligible because the shot still reduces hospitalisation and severe disease, and early vaccination is especially important in a season that began earlier than usual [4] [5] [11]. Masking and other risk‑reduction measures are being advised in some settings as hospitals feel pressure from rising admissions [9] [10].
Limitations: this analysis relies solely on the cited press and UKHSA surveillance summaries; raw lab data and complete vaccine‑efficacy studies are not included in the supplied material (available sources do not mention full primary neutralisation datasets) [2] [4].